Clinical Trial Update: Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study comparing OSI-211 with topotecan in relapsed epithelial ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• OSI-211
• Topotecan (topotecan)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Ovarian Neoplasms | Phase 2 | Status: COMPLETED